Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cambridge Major Expands Capacity

by Ann M. Thayer
September 17, 2012 | A version of this story appeared in Volume 90, Issue 38

Cambridge Major Laboratories has expanded its large-scale active pharmaceutical ingredient facility in Germantown, Wis. The custom manufacturer is among a group of firms that has been investing in U.S. assets, particularly in the Midwest. “Our faith in the ‘invest in the West’ policy initiated a few years ago continues to bear fruit,” CEO Brian Scanlan says. The company says it added reactor capacity and isolation equipment to support increasing demand for commercial and late-stage development products. It plans to add product-containment capabilities at its Weert, the Netherlands, facility later this year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.